Embed Notice

@valhalla @Dangerous_beans Yeah that’s a good model imho, in part because it allows for better cross-subsidisation of both failed and unprofitable drugs, based on drugs that are profitable. One issue is that it also tends to result in more unmet need in orphaned indications, since on a cost/benefit basis it isn’t rational to “waste” finite R&D on areas that have little need (which leaves folks with those conditions SOL). The TGA in Australia can be quite ruthless about this, for example.

And yes I believe OP was posting in the context of the US, where this kind of “socialist” model would be very difficult to deploy (which doesn’t make it any less of a good idea, ofc).